Years before Theranos, the Silicon Valley upstart that promised to revolutionize blood testing, came under harsh public scrutiny in October, a military official raised concerns that the secretive company was violating federal law.
E-mail correspondence obtained by the Post reveals that an official evaluating Theranos’s signature blood-testing technology for the Department of Defense sounded the alarm in 2012 and launched a formal inquiry with the Food and Drug Administration about the company’s intent to distribute its tests without FDA clearance — a problem that has resurfaced this year, leading Theranos to temporarily stop offering almost all of its tests.
Read Full Article »